Anti-erythroblast autoimmunity in early myelodysplastic syndromes

Haematologica

Volumn 92, Issue 1, 2007, Pages 19-26

  Barcellini, Wilma ^a   Zaninoni, Anna ^a   Imperiali, Francesca G ^a   Boschetti, Carla ^a   Colombi, Mariangela ^a   Iurlo, Alessandra ^a   Zanella, Alberto ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Autoimmunity; Bone marrow; Erythroblast; MDS

Indexed keywords

AUTOANTIBODY; CASPASE 3; CYTOKINE; IMMUNOGLOBULIN G; INTERLEUKIN 4; STEROID; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; APOPTOSIS; ARTICLE; AUTOIMMUNITY; BLOOD CULTURE; BONE MARROW; CLINICAL ARTICLE; CONTROLLED STUDY; COOMBS TEST; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROBLAST; ERYTHROPOIESIS; FEMALE; FOLLOW UP; HUMAN; IMMUNOREGULATION; MALE; MYELODYSPLASTIC SYNDROME; PATHOGENESIS; REFRACTORY ANEMIA; SIDEROBLASTIC ANEMIA;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA, REFRACTORY; ANTIGENS, CD45; APOPTOSIS; AUTOIMMUNITY; BONE MARROW CELLS; CASPASE 3; ERYTHROBLASTS; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NF-KAPPA B;

EID: 33846908097     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.10546     Document Type: Article

References (27)

1. Hofmann WK, Lubbert M, Hoelzer D, Phillip Koeffler H. Myelodysplastic syndromes. Hematol J 2004;5:1-8.
2. Harris N, Jaffe E, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, et al. WHO classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the clinical advisory committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999;17:3835-49.
3. Barrett AJ, Saunthararajah Y, Molldrem J. Myelodysplastic syndrome and aplastic anemia: distinct entities or diseases linked by a common pathophysiology? Semin Hematol 2000;37:15-29.
4. Novaretti MC, Sopelete CR, Velloso ER, Rosa MF, Dorlhiac-Llacer PE, Chamone DA. Immunohematological findings in myelodysplastic syndrome. Acta Haematol 2001;105:1-6.
5. Kook H, Zeng W, Guibin C, Kirby M, Young NS, Maciejewski JP. Increased cytotoxic T cells with effector phenotype in aplastic anemia and myelodysplasia. Exp Hematol 2001;29:1270-7.
6. Mufti GJ, Figes A, Hamblin TJ, Oscier DG, Copplestone JA. Immunological abnormalities in myelodysplastic syndromes. I. Serum immunoglobulins and autoantibodies. Br J Haematol 1986;63:143-7.
7. Hamblin TJ. Immunological abnormalities in myelodysplastic syndromes. Semin Hematol 1996; 33:150-62.
8. Enright H, Jacob HS, Vercellotti G, Howe R, Belzer M, Miller W. Paraneoplastic autoimmune phenomena in patients with myelodysplastic syndromes: response to immunosuppressive therapy. Br J Haematol 1995; 91:403-8.
9. Molldrem JJ, Jiang YZ, Stetler-Stevenson M, Mavroudis D, Hensel N, Barrett AJ. Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vβ profiles. Br J Haematol 1998;102:1314-22.
10. Falcone M, Sarvetnick N. Cytokines that regulate autoimmune responses. Curr Opin Immunol 1999;11:670-6.
11. Chervonsky AV. Apoptotic and effector pathways in autoimmunity. Curr Opin Immunol 1999; 11:684-8.
12. Koike M, Ishiyama T, Tomoyasu S, Tsuruoka N. Spontaneous cytokine overproduction by peripheral blood mononuclear cells from patients with myelodysplastic syndromes and aplastic anemia. Leuk Res 1995;19:639-44.
13. Kitagawa M, Saito I, Kuwata T, Yoshida S, Yamaguchi S, Takahashi M, et al. Overexpression of tumor necrosis factor (TNF)-α and interferon (IFN)-γ by bone marrow cells from patients with myelodysplastic syndromes. Leukemia 1997;11:2049-54.
14. Molnar L, Berki T, Hussain A, Nemeth P, Losonczy H. Detection of TNFα expression in the bone marrow and determination of TNFa production of peripheral blood mononuclear cells in myelodysplastic syndrome. Pathol Oncol Res 2000;6:18-23.
15. Allampallam K, Shetty V, Mundle S, Dutt D, Kravitz H, Reddy PL, et al. Biological significance of proliferation, apoptosis, cytokines, and monocyte/macrophage cells in bone marrow biopsies of 145 patients with myelodysplastic syndrome. Int J Hematol 2002;75:289-97.
16. Barcellini W, Clerici G, Montesano R, Taioli E, Morelati F, Rebulla P, et al. In vitro quantification of anti-red blood cell antibody production in idiopathic autoimmune haemolytic anaemia: effect of mitogen and cytokine stimulation. Br J Haematol 2000;111:452-60.
17. Barcellini W, Montesano R, Clerici G, Zaninoni A, Imperiali FG, Calori R, et al. In vitro production of anti-RBC antibodies and cytokines in chronic lymphocytic leukemia. Am J Hematol 2002;71:177-83.
18. Barcellini W, Rizzardi GP, Velati C, Borghi MO, Fain C, Lazzarin A, et al. In vitro production of type 1 and type 2 cytokines by peripheral blood mononuclear cells of HIV-1-negative intravenous drug users. AIDS 1995;9:691-4.
19. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89:2079-88.
20. Voulgarelis M, Giannouli S, Ritis K, Tzioufas AG. Myelodysplasia- associated autoimmunity: clinical and pathophysiologic concepts. Eur J Clin Invest 2004;34:690-700.
21. Yoshida Y. Hypothesis: apoptosis may be the mechanism responsible for the premature intramedullary cell death in the myelodysplastic syndrome. Leukemia 1993;7: 144-6.
22. Zang DY, Goodwin RG, Loken MR, Bryant E, Deeg HJ. Expression of tumor necrosis factor-related apoptosis-inducing ligand, Apo2L, and its receptors in myelodysplastic syndrome: effects on in vitro hemopoiesis. Blood 2001;98:3058-65.
23. Gersuk GM, Beckham C, Loken MR, Kiener P, Anderson JE, Farrand A, et al. A role for tumour necrosis factor-alpha: Fas and Fas-ligand in marrow failure associated with myelodysplastic syndrome. Br J Haematol 1998;103:176-88.
24. Kitagawa M, Yamaguchi S, Takahashi M, Tanizawa T, Hirokawa K, Kamiyama R. Localization of Fas and Fas ligand in bone marrow cells demonstrating myelodysplasia. Leukemia 1998;12:486-92.
25. Mundle SD, Reza S, Ali A, Mativi Y, Shetty V, Venugopal P, et al. Correlation of tumor necrosis factor alpha (TNFα) with high caspase 3-like activity in myelodysplastic syndromes. Cancer Lett 1999;140: 201-7.
26. Bouscary D, Chen YL, Guesnu M, Picard F, Viguier F, Lacombe C, et al. Activity of the caspase-3/CPP32 enzyme is increased in "early stage" myelodysplastic syndromes with excessive apoptosis, but caspase inhibition does not enhance colony formation in vitro. Exp Hematol 2000;28:784-91.
27. Raza A, Gregory SA, Preisler HD. The myelodysplastic syndromes in 1996: complex stem cell disorders confounded by dual actions of cytokines. Leuk Res 1996; 20:881-90.